- There were around 5,400 bladder cancer deaths in the UK in 2014, that’s 15 deaths every day.
- Bladder cancer is the seventh most common cause of cancer death in the UK (2014).
- Bladder cancer accounts for 3% of all cancer deaths in the UK (2014).
- In males in the UK, bladder cancer is the sixth most common cause of cancer death, with around 3,600 deaths in 2014.
- In females in the UK, bladder cancer is the 12th most common cause of cancer death, with around 1,800 deaths in 2014.
- More than half (53%) of bladder cancer deaths in the UK each year are in people aged 80 and over (2012-2014).
- Mortality rates for bladder cancer in the UK are highest in people aged 90+ (2012-2014).
- Since the early 1990s, bladder cancer death rates in the UK have decreased by more than a third for men and by around a quarter for women.
- Bladder cancer deaths in England are more common in people living in the most deprived areas.
- In Europe, around 52,400 people were estimated to have died from bladder cancer in 2012. The UK mortality rate is 10th lowest in Europe for males and eighth highest for females.
- Worldwide around 165,100 people were estimated to have died from bladder cancer in 2012, with mortality rates varying across the world.
Bladder cancer statistics
New cases of bladder cancer, 2013, UK
Deaths from bladder cancer, 2014, UK
Survive bladder cancer for 10 or more years, 2010-11, England and Wales
Preventable cases of bladder cancer, UK
- There were around 10,300 new cases of bladder cancer in the UK in 2013, that’s 28 cases diagnosed every day.
- Bladder cancer is the ninth most common cancer in the UK (2013).
- Bladder cancer accounts for 3% of all new cases in the UK (2013).
- In males in the UK, bladder cancer is the fourth most common cancer, with around 7,500 cases diagnosed in 2013.
- In females in the UK, bladder cancer is the 14th most common cancer, with around 2,900 cases diagnosed in 2013.
- More than half (54%) of bladder cancer cases in the UK each year are diagnosed in people aged 75 and over (2011-2013).
- Since the late 1970s, bladder cancer incidence rates have decreased by more than a quarter (27%) in Great Britain. The decrease is larger in males where rates have decreased by almost a third (30%), than in females where rates have decreased by around a fifth (19%).
- Over the last decade, bladder cancer incidence rates have decreased by a tenth (10%) in the UK, with a similar decrease in males (13%) and females (10%).
- Most bladder cancer cases are diagnosed at an early stage.
- 1 in 39 men and 1 in 110 women will be diagnosed with bladder cancer during their lifetime.
- In Europe, more than 151,000 new cases of bladder cancer were estimated to have been diagnosed in 2012. The UK incidence rate is the lowest in Europe for males and the 13th lowest for females.
- Worldwide, an estimated 429,000 new cases of bladder cancer were diagnosed in 2012, with incidence rates varying across the world.
- Bladder cancer in England is more common in people living in the most deprived areas.
- Bladder cancer is more common in White people than in Asian or Black people.
- In the UK more than 46,500 people were still alive at the end of 2006, up to ten years after being diagnosed with bladder cancer.
- Half (50%) of people diagnosed with bladder cancer in England and Wales survive their disease for ten years or more (2010-11).
- More than half (53%) of people diagnosed with bladder cancer in England and Wales survive their disease for five years or more (2010-11).
- More than 7 in 10 (72%) people diagnosed with bladder cancer in England and Wales survive their disease for one year or more (2010-11).
- Bladder cancer survival is higher in men than women.
- Almost three-quarters of men in England with bladder cancer diagnosed aged 15-49 survive their disease for five years or more, compared with more than 4 in 10 men diagnosed aged 80 and over (2009-2013).
- Almost 6 in 10 women in England diagnosed with bladder cancer aged 50-59 survive their disease for five years or more, compared to less than a third of women diagnosed aged 80 and over (2009-2013).
- Bladder cancer survival trends are difficult to interpret because of changes in classification and coding practices.
- In the 1970s, a third (33%) of people diagnosed with bladder cancer survived their disease beyond ten years, now it's half (50%).
- When diagnosed at its earliest stage, more than 8 in 10 people with bladder cancer will survive their disease for five years or more, compared with around 1 in 10 people when the disease diagnosed at the latest stage.
- A person’s risk of developing cancer depends on many factors, including age, genetics, and exposure to risk factors (including some potentially avoidable lifestyle factors).
- 42% (44% in males and 37% in females) of bladder cancer cases each year in the UK are linked to major lifestyle and other risk factors.
- Smoking is the main avoidable risk factor for bladder cancer, linked to an estimated 37% of bladder cancer cases in the UK.
- An estimated 42% of bladder cancers in the UK are linked to lifestyle factors including smoking, certain occupational exposures (6%), and ionising radiation (3%).
- Coffee drinking may relate to higher bladder cancer risk.
- 'Two-week wait' is the most common route to diagnosing bladder cancer.
- Two week wait is the route with the highest proportion of cases diagnosed at an early stage, for bladder cancer.
- ‘Two-week wait’ standards are met by all countries, ‘31-day wait’ and ‘62 day wait’ are not met by any country for urological cancers.
- Around a tenth of bladder cancer patients receive major surgical resection as part of their cancer treatment.
- Almost 9 in 10 patients had a ‘very good’ or ‘excellent’ patient experience.
- Around three-quarters of patients are given the name of their Clinical Nurse Specialist.
The latest statistics available for bladder cancer in the UK are; incidence 2013, mortality 2014 and survival 2010-2011 (all ages combined) and 2009-2013 (by age).
European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.
Lifetime risk estimates were calculated using incidence, mortality, population and all-cause mortality data for 2012.
Bladder cancer statistics are difficult to interpret because of different and changing classification/coding practices affecting the definition of invasive
Survival statistics give an overall picture of survival and (unless otherwise stated) include all adults (15-99) diagnosed, at all ages,
Stage at diagnosis data is not yet routinely available for the UK due to inconsistencies in the collecting and recording of staging data in the past.
Routes to diagnosis statistics were calculated from cases of cancer registered in England which were diagnosed in 2012-2013. Staging proportions only include patients with a known stage (cases with an unknown stage at diagnosis are not included in the denominator).
Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. Bladder cancer is part of the group 'Urological cancer' for cancer waiting times data. Codes vary per country but broadly include: penis, prostate, testis, other and unspecified male genital organs, kidney, renal pelvis, ureter, bladder, other and unspecified urinary organs, secondary cancers of kidney, renal pelvis, bladder and other unspecified urinary organs.
Cancer surgical resection rates data is for patients diagnosed in England between 2006 and 2010.
Patient Experience data is for adult patients in England with a primary diagnosis of cancer, who were in active treatment between September and November 2013 and who completed a survey in 2014.
Deprivation gradient statistics were calculated using incidence data for three time periods: 1996-2000, 2001-2005 and 2006-2010 and for mortality for two time periods: 2002-2006 and 2007-2011. The 1997-2001 mortality data were only used for the all cancers combined group as this time period includes the change in coding from ICD-9 to ICD-10. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.
You are welcome to reuse this Cancer Research UK statistics content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:
Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.